Ad A. van Bodegraven

Author

Amsterdam UMC Location Vrije Universiteit Amsterdam

Also Known As

A A van Bodegraven, A. A. VAN BODEGRAVEN, A. A. Van Bodegraven, A. A. van Bodegraven, A. A. van Bodegraven, C. J. M. Böhm, A.A. van Bodegraven, Ad A Bodegraven, Ad A van Bodegraven, Ad A. Bodegraven, Ad A. Van Bodegraven

151

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam University Medical Center Utrecht University Medical Center Groningen Radboud University Nijmegen Amsterdam UMC Location University of Amsterdam

About

Ad A. van Bodegraven is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, gastroenterology, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	2.9K
2	Public Health	3	3	135
3	Epidemiology	3	3	209
4	Clinical Nutrition	2	2	52
5	Health Sciences	1	1	29

Ad A. van Bodegraven

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Geert D’Haens, Filip Baert, Gert Van Assche, The Lancet Autoimmune DiseaseImmunosuppressive TherapyImmunologyGastroenterologyClinical Gastroenterology	2008	1.2K
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders, Gut	2012	491
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial Marin J. de Jong, Andrea E. van der Meulen‐de Jong, Mariëlle Romberg‐Camps, The Lancet Wireless TelemedicineRemote Patient MonitoringTelemedicineEhealthGastroenterology	2017	347
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial Cyriel Y. Ponsioen, E. Joline de Groof, Emma J. Eshuis, The Lancet. Gastroenterology & hepatology Terminal IleitisGastroenterologyMulticentre TrialSurgeryClinical Gastroenterology	2017	334
<i>Helicobacter pylori</i>Modulates the T Helper Cell 1/T Helper Cell 2 Balance through Phase-variable Interaction between Lipopolysaccharide and DC-SIGN Mathijs P. Bergman, Anneke Engering, Hermelijn H. Smits, The Journal of Experimental Medicine	2004	314
Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage Hans van Vliet, B. Mary E. von Blomberg, Nobusuke Nishi, Clinical Immunology InflammationWide VarietyAutoimmune DiseaseImmunologyImmune Regulation	2001	270
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) Pieter Dewint, Bettina E. Hansen, Elke Verhey, Gut	2013	258
Hand-Assisted Laparoscopic Versus Open Restorative Proctocolectomy With Ileal Pouch Anal Anastomosis S. Maartense, Michalda S. Dunker, J. F. M. Slors, Annals of Surgery	2004	251
High frequency of early colorectal cancer in inflammatory bowel disease Maurice Lutgens, Frank P. Vleggaar, M.E.I. Schipper, Gut	2008	224
Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts Bindia Jharap, Margien L. Seinen, Nanne K.H. de Boer, Inflammatory Bowel Diseases	2010	197

Page 1